335 related articles for article (PubMed ID: 17051322)
1. 2-Deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma.
Iagaru A; Quon A; Johnson D; Gambhir SS; McDougall IR
Mol Imaging Biol; 2007; 9(1):50-7. PubMed ID: 17051322
[TBL] [Abstract][Full Text] [Related]
2. Merkel cell carcinoma: Is there a role for 2-deoxy-2-[f-18]fluoro-D-glucose-positron emission tomography/computed tomography?
Iagaru A; Quon A; McDougall IR; Gambhir SS
Mol Imaging Biol; 2006; 8(4):212-7. PubMed ID: 16724293
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. 2-Deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer.
Iagaru A; Masamed R; Singer PA; Conti PS
Mol Imaging Biol; 2006; 8(5):309-14. PubMed ID: 16758370
[TBL] [Abstract][Full Text] [Related]
5. The utility of 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma.
Macapinlac HA
Mol Imaging Biol; 2004; 6(4):200-7. PubMed ID: 15262235
[TBL] [Abstract][Full Text] [Related]
6. Whole-Body [
Berzaczy D; Fueger B; Hoeller C; Haug AR; Staudenherz A; Berzaczy G; Weber M; Mayerhoefer ME
Mol Imaging Biol; 2020 Jun; 22(3):739-744. PubMed ID: 31363965
[TBL] [Abstract][Full Text] [Related]
7. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.
Mahner S; Schirrmacher S; Brenner W; Jenicke L; Habermann CR; Avril N; Dose-Schwarz J
Ann Oncol; 2008 Jul; 19(7):1249-1254. PubMed ID: 18356138
[TBL] [Abstract][Full Text] [Related]
8. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
9. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT evaluation of patients with ovarian carcinoma.
Iagaru AH; Mittra ES; McDougall IR; Quon A; Gambhir SS
Nucl Med Commun; 2008 Dec; 29(12):1046-51. PubMed ID: 18987524
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.
Apolo AB; Riches J; Schöder H; Akin O; Trout A; Milowsky MI; Bajorin DF
J Clin Oncol; 2010 Sep; 28(25):3973-8. PubMed ID: 20679618
[TBL] [Abstract][Full Text] [Related]
12. F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas.
Iagaru A; Quon A; McDougall IR; Gambhir SS
Clin Nucl Med; 2006 Dec; 31(12):754-60. PubMed ID: 17117068
[TBL] [Abstract][Full Text] [Related]
13. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
14. F-18 FDG PET/CT in the management of thyroid cancer.
Iagaru A; Kalinyak JE; McDougall IR
Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
[TBL] [Abstract][Full Text] [Related]
15. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
[TBL] [Abstract][Full Text] [Related]
17. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases.
Strobel K; Dummer R; Husarik DB; Pérez Lago M; Hany TF; Steinert HC
Radiology; 2007 Aug; 244(2):566-74. PubMed ID: 17641374
[TBL] [Abstract][Full Text] [Related]
18. Impact of 2-deoxy-2[F-18]fluoro-D-glucose Positron Emission Tomography on the management of patients with advanced melanoma.
Harris MT; Berlangieri SU; Cebon JS; Davis ID; Scott AM
Mol Imaging Biol; 2005; 7(4):304-8. PubMed ID: 16041590
[TBL] [Abstract][Full Text] [Related]
19. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma.
Gritters LS; Francis IR; Zasadny KR; Wahl RL
J Nucl Med; 1993 Sep; 34(9):1420-7. PubMed ID: 8355058
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer.
Wong TZ; Jones EL; Coleman RE
Mol Imaging Biol; 2004; 6(1):55-62. PubMed ID: 15018829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]